ドキソルビシン市場の成長と動向分析レポート

Doxorubicin Market Growth & Trends

The global doxorubicin market size is expected to reach USD 1.53 billion by 2030, registering a CAGR of 6.6% during the forecast period, according to a new report by Grand View Research, Inc.

世界のドキソルビシン市場規模は2030年までに15億3,000万米ドルに達すると予想されており、予測期間中に6.6%のCAGRを記録します。

The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: –

• Leukemia 60,140
• Breast cancer 2,46,660
• Endometrial cancer 60,050
• Gastric cancer 26,370
• Liver cancer 39,230
• Kidney Cancer 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Doxorubicin Market Report Scope

Doxorubicin Market Report Highlights

• In 2023, breast cancer is the largest application of doxorubicin market. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.

• Bladder cancer segment projected to grow at a significant CAGR during the forecast period. Doxorubicin, which has been a standard treatment for advanced bladder cancer, remains a critical component in the management of the disease.

• In 2023, North America held majority of market share of over 37.7% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.

• Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope

                    1.1. Market Segmentation and Scope

                    1.2. Market Definitions

                    1.3. Research Methodology

                        1.3.1. Information Procurement

                        1.3.2. Information or Data Analysis

                        1.3.3. Market Formulation & Data Visualization

                        1.3.4. Data Validation & Publishing

                    1.4. Research Scope and Assumptions

                        1.4.1. List of Data Sources

Chapter 2. Executive Summary

                    2.1. Market Outlook

                    2.2. Segment Outlook

                    2.3. Competitive Insights

Chapter 3. Doxorubicin Market Variables, Trends, & Scope

                    3.1. Market Introduction/Lineage Outlook

                    3.2. Market Size and Growth Prospects (USD Million)

                    3.3. Market Dynamics

                        3.3.1. Market Drivers Analysis

                        3.3.2. Market Restraints Analysis

                    3.4. Doxorubicin Market Analysis Tools

                        3.4.1. Porter’s Analysis

                            3.4.1.1. Bargaining power of the suppliers

                            3.4.1.2. Bargaining power of the buyers

                            3.4.1.3. Threats of substitution

                            3.4.1.4. Threats from new entrants

                            3.4.1.5. Competitive rivalry

                        3.4.2. PESTEL Analysis

                            3.4.2.1. Political landscape

                            3.4.2.2. Economic and Social landscape

                            3.4.2.3. Technological landscape

                            3.4.2.4. Environmental landscape

                            3.4.2.5. Legal landscape

Chapter 4. Doxorubicin Market: Drug Formulation Estimates & Trend Analysis

                    4.1. Segment Dashboard

                    4.2. Doxorubicin Market: Drug Formulation Movement Analysis, 2023 & 2030 (USD Million)

                    4.3. Lyophilized Powder

                        4.3.1. Lyophilized Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    4.4. Doxorubicin Injection

                        4.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 5. Doxorubicin Market: Application Estimates & Trend Analysis

                    5.1. Segment Dashboard

                    5.2. Doxorubicin Market: Application Analysis, 2023 & 2030 (USD Million)

                    5.3. Bladder Cancer

                        5.3.1. Bladder Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    5.4. Kaposi Sarcoma

                        5.4.1. Kaposi Sarcoma Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    5.5. Leukemia

                        5.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    5.6. Lymphoma

                        5.6.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    5.7. Others

                        5.7.1. Others Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 6. Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

                    6.1. Segment Dashboard

                    6.2. Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)

                    6.3. Hospital Pharmacies

                        6.3.1. Hospital Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    6.4. Retail Pharmacies

                        6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

                    6.5. Online Pharmacies

                        6.5.1. Online Pharmacies Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 7. Doxorubicin Market: Regional Estimates & Trend Analysis

                    7.1. Doxorubicin Market Share, By Region, 2023 & 2030 (USD Million)

                    7.2. North America

                        7.2.1. North America Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.2.2. U.S.

                            7.2.2.1. U.S. Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.2.3. Canada

                            7.2.3.1. Canada Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.2.4. Mexico

                            7.2.4.1. Mexico Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                    7.3. Europe

                        7.3.1. Europe Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.2. U.K.

                            7.3.2.1. U.K. Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.3. Germany

                            7.3.3.1. Germany Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.4. France

                            7.3.4.1. France Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.5. Italy

                            7.3.5.1. Italy Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.6. Spain

                            7.3.6.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.7. Denmark

                            7.3.7.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.8. Sweden

                            7.3.8.1. Sweden Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.3.9. Norway

                            7.3.9.1. Norway Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                    7.4. Asia Pacific

                        7.4.1. Asia Pacific

                        7.4.2. Asia Pacific Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.4.3. China

                            7.4.3.1. China Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.4.4. Japan

                            7.4.4.1. Japan Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.4.5. India

                            7.4.5.1. India Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.4.6. South Korea

                            7.4.6.1. South Korea Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.4.7. Australia

                            7.4.7.1. Australia Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.4.8. Thailand

                            7.4.8.1. Thailand Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                    7.5. Latin America

                        7.5.1. Latin America Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.5.2. Brazil

                            7.5.2.1. Brazil Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.5.3. Argentina

                            7.5.3.1. Argentina Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                    7.6. Middle East and Africa

                        7.6.1. Middle East and Africa Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.6.2. Saudi Arabia

                            7.6.2.1. Saudi Arabia Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.6.3. UAE

                            7.6.3.1. UAE Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.6.4. South Africa

                            7.6.4.1. South Africa Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

                        7.6.5. Kuwait

                            7.6.5.1. Kuwait Doxorubicin Market Estimates and Forecasts, 2018 – 2030 (USD Million)

Chapter 8. Competitive Landscape

                    8.1. Recent Developments & Impact Analysis by Key Market Participants

                    8.2. Company Categorization

                    8.3. Company Heat Map Analysis

                    8.4. Company Profiles

                        8.4.1. Pfizer Inc.

                            8.4.1.1. Participant’s Overview

                            8.4.1.2. Financial Performance

                            8.4.1.3. Product Benchmarking

                            8.4.1.4. Recent Developments/ Strategic Initiatives

                        8.4.2. Johnson & Johnson Services, Inc.

                            8.4.2.1. Participant’s Overview

                            8.4.2.2. Financial Performance

                            8.4.2.3. Product Benchmarking

                            8.4.2.4. Recent Developments/ Strategic Initiatives

                        8.4.3. Sun Pharmaceutical Industries Ltd

                            8.4.3.1. Participant’s Overview

                            8.4.3.2. Financial Performance

                            8.4.3.3. Product Benchmarking

                            8.4.3.4. Recent Developments/ Strategic Initiatives

                        8.4.4. Cipla.

                            8.4.4.1. Participant’s Overview

                            8.4.4.2. Financial Performance

                            8.4.4.3. Product Benchmarking

                            8.4.4.4. Recent Developments/ Strategic Initiatives

                        8.4.5. Cadila Pharmaceuticals.

                            8.4.5.1. Participant’s Overview

                            8.4.5.2. Financial Performance

                            8.4.5.3. Product Benchmarking

                            8.4.5.4. Recent Developments/ Strategic Initiatives

                        8.4.6. Novartis AG

                            8.4.6.1. Participant’s Overview

                            8.4.6.2. Financial Performance

                            8.4.6.3. Product Benchmarking

                            8.4.6.4. Recent Developments/ Strategic Initiatives

                        8.4.7. Dr. Reddy’s Laboratories Ltd.

                            8.4.7.1. Participant’s Overview

                            8.4.7.2. Financial Performance

                            8.4.7.3. Product Benchmarking

                            8.4.7.4. Recent Developments/ Strategic Initiatives

                        8.4.8. SRS Life Sciences

                            8.4.8.1. Participant’s Overview

                            8.4.8.2. Financial Performance

                            8.4.8.3. Product Benchmarking

                            8.4.8.4. Recent Developments/ Strategic Initiatives

                        8.4.9. MicroBiopharm Japan Co., Ltd.

                            8.4.9.1. Participant’s Overview

                            8.4.9.2. Financial Performance

                            8.4.9.3. Product Benchmarking

                            8.4.9.4. Recent Developments/ Strategic Initiatives

                        8.4.10. Baxter

                            8.4.10.1. Participant’s Overview

                            8.4.10.2. Financial Performance

                            8.4.10.3. Product Benchmarking

                            8.4.10.4. Recent Developments/ Strategic Initiatives

Grand View Researchについて

Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ 1

ライセンスタイプ 2

ライセンスタイプ 3

ライセンスタイプ 4

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス（インディビジュアルライセンス）
    • 1名のみレポートファイル（印刷不可）をご利用いただけます。
  • チームライセンス
    • 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
  • コーポレートライセンス
    • 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
    • 「関連会社」の範囲についてはお気軽にお問い合わせください。
• 納品形態
  • オンラインダウンロード
• 納期
  • ご注文後1～7営業日　※レポートにより異なります。

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

最新出版レポート

• ARクラウド市場規模、成長と動向分析レポート 2025-2033年
• ノーコードAIプラットフォーム市場規模、成長と動向分析レポート 2025-2033年
• 量子コンピューティングにおけるAI最適化市場規模、成長と動向分析レポート 2025-2033年
• ワイヤレス状態監視システム市場規模、成長と動向分析レポート 2025-2033年
• ゲームストリーミング市場規模、成長と動向分析レポート 2025-2033年

出版レポート一覧